期刊
GENE THERAPY
卷 27, 期 9, 页码 407-416出版社
SPRINGERNATURE
DOI: 10.1038/s41434-020-0156-6
关键词
-
类别
资金
- Muscular Dystrophy Canada
- Friends of Garrett Cumming Research Fund
- HM Toupin Neurological Science Research Fund
- Canadian Institutes of Health Research (CIHR)
- Alberta Innovates: Health Solutions (AIHS)
- Jesse's Journey
- Canada Foundation for Innovation (CFI)
- Alberta Advanced Education and Technology
- Women and Children's Health Research Institute (WCHRI)
Duchenne muscular dystrophy (DMD) is one of the most common lethal muscle-wasting disorders affecting young boys caused by mutations in the DMD gene. Exon skipping has emerged as a promising therapy for DMD. Antisense oligonucleotides (AONs) are designed to induce the skipping of exon(s), in order to restore the reading frame, and therefore, allow for dystrophin expression. Eteplirsen and golodirsen, AONs for DMD exons 51 and 53 skipping, have been recently approved by the FDA. Viltolarsen, an AON for DMD exon 53 skipping, was approved in Japan earlier this year. Although promising, the efficacy of eteplirsen and AON sequence employed remain controversial. In addition, exon skipping faces challenges including the applicability and delivery. This article reviews and discusses exon skipping and the current advances being made in the field, on drugs, multi-exon skipping, sequence design, and applicability. We also discuss challenges and future directions that will facilitate the development of exon skipping therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据